Stockreport

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-ß Antibodies for Idiopathic Pulmonary Fibrosis

Surrozen, Inc.  (SRZN) 
PDF SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics [Read more]